

Tatiana Koudriavtseva

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2386861/tatiana-koudriavtseva-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

914
citations

17
h-index

29
g-index

57
ext. papers

1,065
ext. citations

3.6
avg, IF

4.54
L-index

#	Paper	IF	Citations
52	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <i>Clinical Drug Investigation</i> , 2018 , 38, 653-671	3.2	152
51	Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 61, 251-8	5.5	76
50	Involvement of the limbic system in multiple sclerosis patients with depressive disorders. <i>Biological Psychiatry</i> , 1996 , 39, 970-5	7.9	69
49	Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 285-7	5.5	61
48	Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. <i>PLoS ONE</i> , 2013 , 8, e65184	3.7	59
47	Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. <i>Neurology</i> , 1998 , 50, 403-6	6.5	39
46	Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response. <i>Neural Regeneration Research</i> , 2016 , 11, 1727-1730	4.5	34
45	The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability. <i>Neurological Sciences</i> , 2012 , 33, 575-84	3.5	29
44	Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. <i>Clinical and Experimental Immunology</i> , 2014 , 176, 320-6	6.2	26
43	No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1997 , 96, 372-4	3.8	26
42	MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1997 , 3, 221-5	5	26
41	Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 579-84	5.5	22
40	Concurrence of multiple sclerosis and brain tumors. <i>Frontiers in Neurology</i> , 2015 , 6, 40	4.1	20
39	The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. <i>Acta Neurologica Scandinavica</i> , 1997 , 95, 201-7	3.8	20
38	Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis. <i>Neuroscience Letters</i> , 2015 , 606, 156-60	3.3	18
37	Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. <i>International Journal of Neuroscience</i> , 2019 , 129, 593-597	2	18
36	The prevalence of multiple sclerosis in central Italy. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1432-6	5	17

35	Perampanel in brain tumor-related epilepsy: Observational pilot study. <i>Brain and Behavior</i> , 2020 , 10, e01612	3.4	14
34	High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes. <i>Neurological Sciences</i> , 2014 , 35, 1737-41	3.5	14
33	Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. <i>Frontiers in Neurology</i> , 2014 , 5, 119	4.1	13
32	A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018 , 9, 1175	4.1	12
31	Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study). <i>Frontiers in Neurology</i> , 2020 , 11, 592	4.1	12
30	Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. <i>Frontiers in Neurology</i> , 2015 , 6, 63	4.1	12
29	Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S380-2	3.5	12
28	Fatal herpetic encephalitis during brain radiotherapy in a cerebral metastasized breast cancer patient. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 137-40	4.8	11
27	Association between anemia and multiple sclerosis. <i>European Neurology</i> , 2015 , 73, 233-237	2.1	10
26	Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Journal of Neurology</i> , 2014 , 261, 2028-9	5.5	10
25	Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report. <i>Oncology Letters</i> , 2016 , 12, 2716-2719	2.6	10
24	Interferon- β therapy and risk of thrombocytopenia in multiple sclerosis patients. <i>Neurological Sciences</i> , 2015 , 36, 2263-8	3.5	9
23	Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 226	3.3	8
22	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 527-535	4.8	7
21	Brain perfusion by arterial spin labeling MRI in multiple sclerosis. <i>Journal of Neurology</i> , 2015 , 262, 1769-75	5.15	6
20	HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence. <i>Journal of NeuroVirology</i> , 2017 , 23, 147-151	3.9	5
19	Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020 , 11, 548604	8.4	4
18	Neuroprotective strategies in the prevention of chemotherapy-induced neuropathies. <i>Supportive Care in Cancer</i> , 2013 , 21, 1-2	3.9	4

17	A possible role of impaired cell-mediated immunity in the pathogenesis of tumefactive demyelinating lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 184-185	4	3
16	From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study. <i>European Neurology</i> , 2014 , 71, 233-41	2.1	3
15	PPIs as possible risk factor for copper deficiency myelopathy. <i>Journal of the Neurological Sciences</i> , 2015 , 349, 258-9	3.2	2
14	Brain perfusion and vasoreactivity in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2015 , 36, E27-8	4.4	2
13	Leptomeningeal carcinomatosis in aggressive germ non-seminoma testicular tumor: a case report and review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2012 , 114, 1081-5	2	2
12	A possible case of Hashimoto's encephalopathy after surgery and radiometabolic therapy for thyroid carcinoma. <i>Neurological Sciences</i> , 2013 , 34, 1489-91	3.5	2
11	Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016 , 371, 79-80	3.2	1
10	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 211-216	4.8	1
9	Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. <i>EXCLI Journal</i> , 2021 , 20, 1152-1169	2.4	1
8	Commentary: Acute Hemorrhagic Leukoencephalitis (Weston-Hurst Syndrome) in a Patient with Relapse-Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2016 , 7, 207	8.4	1
7	Neurocognitive evaluation in older adult patients affected by glioma. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 701-708	3.6	1
6	Multiple sclerosis activated by anti-tumor necrosis factor (Etanercept) and the genetic risk. <i>Neurology India</i> , 2016 , 64, 1042-4	0.7	0
5	Commentary: Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-up Observations. <i>Frontiers in Neurology</i> , 2016 , 7, 222	4.1	0
4	Brain fibrinogen deposition plays a key role in MS pathophysiology - Commentary. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1437-1439	5	
3	Profile of neuromyelitis optica and spectrum disorders in an Indian cohort. <i>Journal of Neurosciences in Rural Practice</i> , 2015 , 6, 295-6	1.1	
2	Tumefactive Demyelinating Lesions and Pregnancy. <i>Neurology India</i> , 2019 , 67, 1519-1521	0.7	
1	Narcolepsy in midbrain structural lesion. <i>Annals of Indian Academy of Neurology</i> , 2016 , 19, 404-5	0.9	